Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04987762 · ClinicalTrials.gov registry record · Phase 4
Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children
A Phase 4 study, sponsored by Purdue Pharma.
- Terminated
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
NCT04987762 is a Phase 4 study that was terminated before completion, run by Purdue Pharma. The registered enrollment target is 103 participants.
The verdict
NCT04987762, a Phase 4 study, was terminated before completion, sponsored by Purdue Pharma.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety of Adhansia XR in children and to characterize the pharmacokinetics (PK) in 4 to 5 year-olds.
Interventions
- DRUG Adhansia XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2021-08-03 |
| Est. Completion | 2022-04-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04987762
The ClinicalTrials.gov registry entry for NCT04987762 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adhansia XR is the first listed.
NCT04987762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04987762 about?
NCT04987762 is a clinical study titled "Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children". The purpose of this study is to assess the long-term safety of Adhansia XR in children and to characterize the pharmacokinetics (PK) in 4 to 5 year-olds.
What is the current status of trial NCT04987762?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2021-08-03. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT04987762?
The interventions under investigation include: Adhansia XR (DRUG).
Who is sponsoring clinical trial NCT04987762?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.